登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688278 证券简称：特宝生物 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 第一季度财务报表是否经审计 一、主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 ■ (二)非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 ■ 对公司将《公开发行证券的公司信息披露解释性公告第1号一一非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号一一非经常性 损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。 □适用 √不适用 □是 √否 (三)主要会计数据、财务指标发生变动的情况、原因 √适用 □ ...

Financial Performance - The company's operating revenue for Q1 2025 reached ¥673,345,118.05, representing a 23.48% increase compared to ¥545,302,286.89 in the same period last year[3] - Net profit attributable to shareholders was ¥182,128,916.89, a 41.40% increase from ¥128,807,591.33 year-over-year[3] - Basic earnings per share increased by 40.63% to ¥0.45, compared to ¥0.32 in the same period last year[3] - Total operating revenue for Q1 2025 reached ¥673,345,118.05, a 23.5% increase from ¥545,302,286.89 in Q1 2024[16] - Net profit for Q1 2025 was ¥182,128,916.89, representing a 41.3% increase compared to ¥128,807,591.33 in Q1 2024[17] Cash Flow and Assets - The net cash flow from operating activities surged by 162.81%, amounting to ¥206,740,177.80, up from ¥78,663,848.24 in the previous year[3] - The company's cash and cash equivalents amounted to RMB 528,072,404.71, up from RMB 371,821,698.43, indicating a significant increase of about 42.03%[12] - Total assets at the end of the reporting period were ¥3,179,123,636.38, a 4.22% increase from ¥3,050,414,835.58 at the end of the previous year[4] - The total assets of the company rose to ¥3,179,123,636.38 in Q1 2025 from ¥3,050,414,835.58 in Q1 2024, marking an increase of 4.2%[15] - The company reported a cash outflow of CNY 614,579,315.86 from operating activities, which is an increase from CNY 550,264,204.09 in the previous year[19] Research and Development - Research and development expenses totaled ¥77,188,385.02, marking a 38.77% increase from ¥55,622,956.59 in the previous year, accounting for 11.46% of operating revenue[3] - Research and development expenses for Q1 2025 were ¥66,748,824.30, up 53.3% from ¥43,575,928.52 in Q1 2024, indicating a strong focus on innovation[16] Shareholder Information - The company reported a total of 7,468 common shareholders at the end of the reporting period[6] - The top shareholder, Yang Ying, holds 33.94% of the shares, totaling 138,077,266 shares[7] Community and Health Initiatives - The company has committed to additional donations totaling RMB 8 million for various hepatitis-related projects, with RMB 4 million already disbursed by the end of the reporting period[9] - The company has also donated RMB 2.7 million for the "Oasis Project" aimed at reducing liver cancer incidence among hepatitis patients, with total donations reaching RMB 31 million by the end of the reporting period[10] - The company plans to continue its support for hepatitis research and treatment initiatives, with ongoing projects and additional funding commitments[11] - The company is actively involved in community health initiatives, contributing to various projects aimed at improving public health outcomes related to hepatitis[9] Liabilities and Equity - Total liabilities decreased to ¥429,839,424.62 in Q1 2025 from ¥497,098,543.83 in Q1 2024, a reduction of approximately 13.5%[14] - Total equity attributable to shareholders increased to ¥2,749,284,211.76 in Q1 2025 from ¥2,553,316,291.75 in Q1 2024, reflecting a growth of 7.7%[15] Inventory and Receivables - Accounts receivable decreased to RMB 654,023,595.24 from RMB 771,496,539.39, representing a decline of approximately 15.19%[12] - Inventory increased to RMB 285,459,731.42 from RMB 263,546,426.51, showing a growth of about 8.29%[13] Financial Management - The company reported a financial asset impairment loss of ¥779,811.54 in Q1 2025, compared to ¥127,378.79 in Q1 2024, highlighting increased caution in asset management[17] - Deferred income increased to ¥40,555,586.47 in Q1 2025 from ¥32,961,392.76 in Q1 2024, indicating growth in future revenue recognition[14]

特宝生物公告，2025年第一季度营收为6.73亿元，同比增长23.48%；净利润为1.82亿元，同比增长 41.40%。 ...

Summary of Conference Call Company and Industry - The conference call primarily discusses **特保生物 (TeBao Bio)**, a company in the **pharmaceutical industry**, focusing on **clinical cures for hepatitis B** and related treatments. Key Points and Arguments 1. **Financial Performance**: - The company reported a **net profit of 828 million yuan**, a **49% increase year-over-year**. The **deducted net profit** was **827 million yuan**, reflecting a **42.73% growth**. This performance is attributed to the increasing recognition of their product, **派格宾 (Pegbivac)**, in the market and improved management efficiency, leading to a reduction in overall expense ratios and enhanced profitability [2][3][21]. 2. **Product Development**: - The company is focusing on **immunology and metabolic diseases**, with ongoing research and development projects. Notably, **Pegbivac** has received clinical trial approvals for new indications, including **clinical cure for hepatitis B** and applications in treating **thrombocytopenia** [3][11][14]. 3. **Clinical Trials and Regulatory Approvals**: - The company submitted an **NDA (New Drug Application)** for **Pegbivac** in March 2024, which is currently under review. This submission is significant as it is the first global NDA for a clinical cure for hepatitis B [5][10][11]. 4. **Market Penetration and Treatment Efficacy**: - The penetration rate of antiviral treatments remains low, indicating a substantial market opportunity. The company believes that as scientific understanding and treatment options improve, the acceptance and demand for hepatitis B treatments will increase [20][21][24]. 5. **Collaborations and Partnerships**: - The company has established collaborations with various organizations, including **九天生物 (Nine Sky Bio)**, to enhance its product pipeline and leverage advanced technologies in gene therapy and immunotherapy [14][25]. 6. **Future Outlook**: - The management expressed confidence in becoming a leader in the field of clinical cures for hepatitis B and related diseases. They anticipate continued growth in R&D investments aligned with project needs and market demands [11][37]. Other Important but Possibly Overlooked Content 1. **Sales Strategy**: - There is a focus on expanding the sales team in anticipation of product approvals, although the current hiring pace is cautious due to pending regulatory approvals [36]. 2. **Research and Development Focus**: - The company emphasizes that R&D investments will be driven by the need to solve clinical problems rather than merely increasing the number of projects. This strategic approach aims to ensure that resources are allocated effectively to high-potential areas [37]. 3. **Patient Engagement and Market Dynamics**: - The management highlighted the importance of educating patients and healthcare providers about the benefits of achieving clinical cures for hepatitis B, which could drive demand and acceptance in the market [30][32]. 4. **Long-term Vision**: - The company aims to address the broader population of hepatitis B patients, including those in non-active phases, by enhancing treatment options and improving patient outcomes through innovative therapies [29][31]. This summary encapsulates the critical insights from the conference call, reflecting the company's strategic direction, financial health, and market opportunities within the pharmaceutical industry.

Investment Rating - The report assigns a "Buy" rating for the company, marking the first coverage of the stock [6]. Core Views - The company is experiencing robust growth in the domestic insulin market, with both volume and price increasing due to successful participation in centralized procurement [5][6]. - The company is actively advancing its innovative research and development pipeline, with promising data from its GLP-1 receptor agonist GZR18 and long-acting insulin GZR4 [5][6]. - The company is expanding its international presence, with increasing overseas sales and successful entry into emerging markets [5][6]. Summary by Sections 1. Market Position and Growth - The company is a leading player in the diabetes market, with a comprehensive insulin product pipeline and significant market share growth due to centralized procurement [9][12]. - In 2024, the company achieved a revenue of 22.45 billion yuan, a year-on-year increase of 17.81%, and a net profit of 5.07 billion yuan, up 90.36% [5][12]. 2. Research and Development - The company has a complete insulin research pipeline, including both marketed products and innovative drugs in development, such as GZR18 and GZR4 [34][39]. - GZR18 has shown significant weight loss results in clinical trials, indicating its potential as a best-in-class (BIC) treatment [36][37]. 3. International Expansion - The company is actively pursuing international markets, with successful product registrations and sales in regions such as Latin America and Asia-Pacific [43][44]. - The company’s overseas revenue reached 2.27 billion yuan in 2023, reflecting a year-on-year growth of 13.31% [44]. 4. Financial Projections and Valuation - The company is projected to achieve net profits of 6.52 billion yuan in 2024, 11.50 billion yuan in 2025, and 14.97 billion yuan in 2026, with corresponding P/E ratios of 40, 23, and 17 [6][12]. - The company's P/E valuation for 2025 is estimated at 23 times, which is lower than the average of comparable companies at 32 times [6].

证券代码：688278 证券简称：特宝生物 公告编号：2025-014 厦门特宝生物工程股份有限公司 关于股东大会开设网络投票提示服务的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 厦门特宝生物工程股份有限公司（以下简称"公司"）于2025年3月28日披露了关于召开2024年年度股东 大会的通知，公司拟于2025年4月18日14:00召开2024年年度股东大会，本次会议采用现场投票和网络投 票相结合的表决方式，具体内容详见公司于上海证券交易所网站（www.sse.com.cn）披露的《关于召开 2024年年度股东大会的通知》（公告编号：2025-013）。 特此公告。 厦门特宝生物工程股份有限公司 董事会 为更好地服务广大中小投资者，确保有投票意愿的中小投资者能够及时参会、及时投票，公司拟使用上 证所信息网络有限公司（以下简称"上证信息"）提供的股东大会提醒服务，委托上证信息通过发送智能 短信等形式，根据股权登记日的股东名册主动提醒股东参会投票，向每一位投资者主动推送股东大会参 会邀请、议案情况等信息。投资者在收到 ...

Core Viewpoint - The company is actively advancing its clinical research and product pipeline in the field of chronic hepatitis B treatment, particularly focusing on the approval and market penetration of its drug, Paigebin, and its combination therapies [2][3]. Group 1: Clinical Developments - The latest approval timeline for the clinical cure indication for chronic hepatitis B is expected to be submitted to the National Medical Products Administration in March 2024, currently under technical review [2]. - The establishment of clinical cure outpatient clinics is ongoing, which is anticipated to positively impact sales by enhancing treatment standardization and increasing patient awareness [2]. - The company is also progressing with the registration application for its growth hormone product, which was accepted in January 2024 and is currently under technical review [2]. Group 2: Research and Development Strategy - The company plans to increase R&D investment in line with clinical needs, focusing on immunology and metabolism, with an upward trend in overall R&D spending as more projects enter clinical research [2][3]. - The company has established collaborations for various products, including ongoing preclinical studies and Phase I clinical trials, indicating a robust pipeline in liver disease and gene therapy [2][3]. Group 3: Market Insights and Future Outlook - The penetration rate of long-acting interferon in chronic hepatitis B treatment remains low, but the company believes that new therapies and combination strategies will increase the patient population receiving antiviral treatment [3]. - The company anticipates that the market for long-acting interferon will expand as new drugs for hepatitis B are launched, supported by evidence showing interferon’s effectiveness in reducing liver cancer risk [3]. - The company is exploring various real-world research projects to optimize hepatitis B treatment strategies, aiming to broaden the definition and scope of clinical cure populations [3].

Group 1 - The core point of the news is the significant block trade of TEBIO on April 7, where 648,000 shares were traded at a price of 83.30 yuan, representing a premium of 14.99% over the closing price of the day [1][2] - The buyer of the block trade was GF Securities Co., Ltd., while the seller was Guojin Securities Co., Ltd. [1][2] - In the last three months, TEBIO has recorded a total of five block trades, with a cumulative transaction amount of 145 million yuan [1] Group 2 - TEBIO's latest closing price was 72.44 yuan, reflecting a decline of 7.54% on the day, with a turnover rate of 1.13% and a total trading volume of 336 million yuan [1] - Over the past five days, TEBIO's stock has decreased by 8.65%, with a total net outflow of funds amounting to 32.21 million yuan [1] - The latest margin financing balance for TEBIO is 339 million yuan, with a slight increase of 850,800 yuan over the past five days, representing a growth rate of 0.25% [2] Group 3 - Four institutions have provided ratings for TEBIO in the past five days, with the highest target price set at 87.04 yuan by Dongfang Securities [2]

Investment Rating - The report maintains a "Recommended" rating for the industry, indicating a positive outlook for the sector's fundamentals and expectations for the industry index to outperform the benchmark index [4]. Core Insights - The pharmaceutical industry is primarily driven by domestic demand, with most sub-sectors minimally affected by tariff impacts, such as medical services, innovative domestic drugs, traditional Chinese medicine, and pharmacy/retail [1][3]. - There is significant potential for import substitution in high-import sectors like blood products, certain medical devices, and key components, which are expected to benefit marginally from the current tariff situation [1]. - The report highlights specific sectors to watch, including blood products, domestic consumption-related sectors, and medical devices, which are poised for growth due to favorable policies and market conditions [2]. Summary by Relevant Sections Blood Products - The overseas share of human albumin exceeds 60%, and with tariffs on imported albumin, domestic prices are expected to recover. The "14th Five-Year Plan" for new plasma stations is also promising. Companies to focus on include Palin Biotech, Tiantan Biological, and Boya Biological [2]. Domestic Consumption - External impacts are minimal, and consumption policies are catalyzing recovery in certain areas. Key companies include medical services (e.g., Aier Eye Hospital, Tongce Medical), beauty services (Aimeike), pharmacies (Yifeng Pharmacy, Dazhong Pharmacy), and traditional Chinese medicine (Dong-E E-Jiao, China Resources Sanjiu) [2]. Medical Devices - For core components, the domestic market for medical CT tubes is largely dominated by imports, with potential benefits from anti-dumping investigations. Companies to watch include Yirui Technology and United Imaging Healthcare [2]. - In consumables, the domestic market for electrophysiology is under 10% localization, with U.S. companies leading. Companies like Huitai Medical and Microelectrophysiology are expected to benefit from increased localization [2]. - In vitro diagnostics (IVD) are also highlighted, with certain leading foreign companies facing tariffs that may accelerate import substitution. Recommended companies include New Industries, Mindray Medical, Antu Biology, and Yanhui Long [2]. Pharmaceuticals - The report indicates that the pharmaceutical sector is largely unaffected by tariffs, with a focus on domestic innovation. Companies to monitor include Heng Rui Medicine, Innovent Biologics, and Fuhong Hanlin [3].

Group 1: Baili Tianheng - In 2024, Baili Tianheng achieved operating revenue of 582.27 million yuan, a year-on-year increase of 936.31%, and net profit of 370.75 million yuan, turning a profit [1] - The company received an $800 million upfront payment from BMS as part of its innovative oncology drug combination [1] - Multiple clinical trials for BL-B01D1 are ongoing in China and the U.S., including several Phase III trials [1] - The company plans to increase R&D investment to 1.443 billion yuan in 2024 and continue to expand in 2025 [1] Group 2: Teabo Bio - Teabo Bio's application for the marketing authorization of Pegbivac is currently under technical review after being accepted in March 2024 [2] - The company is also advancing the registration of long-acting growth hormone and SKG0201, with applications accepted in January 2024 [2] - Teabo Bio emphasizes the strategic significance of acquiring Jiutian Bio and plans to increase R&D investment focusing on breakthrough technology platforms [2] Group 3: Hongyuan Electronics - In 2024, Hongyuan Electronics experienced an 8.57 percentage point decline in gross margin due to falling prices of high-reliability ceramic capacitors and an increase in low-margin product sales [3] - The company reported a 56.11% revenue growth in microcontrollers and integrated circuit products [3] - Major clients account for 71.09% of sales revenue, primarily from China Electronics Technology Group [3] Group 4: Lens Technology - Lens Technology is rapidly developing in automotive, smart terminal, and humanoid robot sectors, collaborating with over 30 smart car brands [4] - The company expects significant growth in its smart retail terminal business and aims to become a core manufacturing platform for embodied intelligent hardware [4] - Lens Technology has made progress in developing ultra-thin laminated glass for automotive applications, with expectations to introduce it to leading domestic new energy vehicle brands this year [4]